Heart surgery bleeding study tests best drug dose
NCT ID NCT07164300
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study compares three different doses of the drug tranexamic acid in 150 adults having elective heart surgery with a heart-lung machine. The goal is to find which dose best controls bleeding and reduces the need for blood transfusions. Researchers will measure how long the drug works and its levels in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tranexamic acid
- What this could lead to
- If successful, this study could help doctors choose the best dose of tranexamic acid to reduce bleeding and transfusions during heart surgery.
- What could go wrong
- This is a small, early-phase trial with 150 participants. Different doses may not show clear benefits, and individual patient responses can vary.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVERSE DRUG EVENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital of Ioannina
RECRUITINGIoannina, Greece
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New study tracks COVID-19 vaccine side effects in kids ages 5 to 16
- Can a simple drug make nose jobs safer and less bruised?
- Massive study aims to crack the code on Kids' medications
- New scoring tool aims to predict Drug-Related ER returns
- Your own blood may be best during heart surgery: pilot study tests new approach
- Massive study to uncover hidden mental toll of cancer